The red bars indicate transmembrane regions as predicted by TMHMM (Krogh et al., 2001) , with the green circles palmitoylation sites (Berditchevski et al., 2002) . The blue Y indicates an N-linked glycosylation site (Fitter et al., 1995) and the light blue lines indicate approximate sites of potential di-sulphide bridges (Seigneuret et al., 2001) .
Localisation
Plasma membrane, endosomes, endothelial cell junctions and hemidesmosomes in basal epithelial cells (Sincock et al., 1999; Sterk et al., 2000) .
Function
CD151 is a major component of tetraspanin enriched microdomains, which are platforms for assembly of membrane signalling complexes (Hemler et al., 2005; Charrin et al., 2009) . CD151 functions in signal transduction through forming direct complexes with integrins particularly alpha3beta1, alpha6beta1, alpha6beta4 and alphaIIbbeta3, thereby influencing a variety of cell functions including motility and adhesion which are outlined further below. CD151 also affects matrix metalloproteinase activity, with overexpression of CD151 in human melanoma cells resulting in increased expression of MMP9 (Hong et al., 2006) . CD151 has been shown to interact with promatrix metalloptroteinase 7 in osteoarthritic cartilage and regulate its activity (Fujita et al., 2006) . In endothelial cells CD151 associates with the matrix metalloproteinase MT1-MMP and regulates its collagenolytic activity (Yañez-Mó et al., 2008) .
Homology
Tetraspanin protein family. This protein family has 33 members in humans and is well conserved throughout vertebrates and also present in invertebrates. Key characteristics include the presence of 4 transmembrane domains with both N-and C-terminals in the cytoplasm, conserved cysteine-containing motifs and disulphide bonds in the large extra cellular loop and charged residues in the transmembrane domains.
Germinal
Homozygous 1bp insertion, G383, resulting in a frameshift at Lys127 and a truncated protein at codon 140. Homozygous G533A substitution resulting in an Arg178His mutation. Homozygous C511T substitution resulting in an Arg171His mutation.
Implicated in

Note
In vitro studies
In vitro assays on Cd151-null keratinocytes, showed lack of migration compared to wild-type keratinocytes (Geary et al., 2008) . Over-expression and knock-down studies of CD151 in various cell lines generally show that CD151 promotes migration and adhesion, however these finding are influenced by cell type and extracellular matrix components and primarily appear to be modified by the expression of the integrin alpha3beta1 (Berditchevski et al., 2002; Winterwood et al., 2006; Liu et al., 2007; Yang et al., 2008) . CD151 is down-regulated by HIF-1alpha in colon cancer cells and is re-expressed upon normal oxygenation. This is proposed to allow detachment from the primary tumour and re-attachment at sites of metastasis (Chien et al., 2008) . Oncogenesis Increased CD151 expression may lead to enhanced tumour progression and metastatic capacity based on enhanced motility, migration and adhesion of CD151 expressing cells. Antibodies to CD151 blocked in vivo metastasis in model systems (Testa et al., 1999; Zijlstra et al., 2008) . Xenograft breast cancer models involving silencing of CD151 showed a delay in tumour formation (Yang et al., 2008) . CD151 expression is increased in metastasis compared to primary tumour site in colon cancer (Chien et al. 2008 ).
Prostate cancer
Note
Immunohistochemical detection of CD151 in a prostate cancer tissue specimens had greater prognostic value than Gleason grading (Ang et al., 2004) . Prognosis High CD151 expression was indicative of poor outcome.
Oncogenesis
High CD151 expression indicated poor survival outcome, suggesting a role for CD151 in enhancing tumourigenesis or resistance to treatment. Also refer to 'In vitro studies'.
Gingival squamous cell carcinoma
Note Real-time PCR analysis of CD151 gene expression compared to GAPDH was analysed (Hirano et al., 2009) . Assessment of protein expression by immunohistochemistry correlated with gene expression however no statistical analyses were performed on protein expression. Prognosis High CD151 expression was indicative of poor outcome. Oncogenesis High CD151 expression indicated poor survival outcome, suggesting a role for CD151 in enhancing tumourigenesis or resistance to treatment. Also refer to 'In vitro studies'.
Colon cancer
Note
Real-time PCR analysis of CD151 gene expression compared to beta-actin was analysed (Hashida et al., 2003) . Assessment of protein expression by immunohistochemistry correlated with gene expression however no statistical analyses were performed on protein expression. Prognosis High CD151 expression was indicative of poor outcome. Oncogenesis High CD151 expression indicated poor survival outcome, suggesting a role for CD151 in enhancing tumourigenesis or resistance to treatment. Also refer to 'In vitro studies'.
Hepatocellular carcinoma
Note
Real-time PCR analysis of CD151 gene expression compared to GAPDH was analysed. Assessment of protein expression by immunohistochemistry and immunoblotting generally correlated with gene expression. CD151 expression was increased in hepatocellular carcinomas compared to normal liver tissues (Ke et al., 2009 ). Immunohistochemical analysis of tissue microarrays identified a positive correlation between CD151 expression and aggressive histopathological factors such as vascular invasion and poor tumour differentiation. CD151 expression was also indicative of poor outcome (Ke et al., 2009 
Breast cancer
Note
Immunohistochemical analysis of CD151 expression in a cohort of invasive ductal carcinoma identified a significantly higher risk of death from breast cancer in CD151 positive tumours compared to CD151 negative tumours. CD151 expression was also positively associated with the involvement of regional lymph nodes. No associations between CD151 expression and other clinical factors including estrogen receptor status were found (Sadej et al.,2009) . Immunohistochemical analysis of CD151 in breast tissue Microarrays identified positive correlations between CD151 expression and high tumour grade as well as negativity for the estrogen receptor. No other associations were identified between CD151 expression and clinical factors (Yang et al., 2008) . Associations between CD151 expression and outcome were not able to be made due to unavailability of data. Prognosis High CD151 expression was indicative of poor outcome. Oncogenesis High CD151 expression indicated poor survival outcome, suggesting a role for CD151 in enhancing tumourigenesis or resistance to treatment. Also refer to 'In vitro studies'.
Pancreatic cancer
Note
Immunohistochemical analysis of pancreatic cancer cell lines and pancreatic tumours identified high CD151 expression associated with tumours/cell lines compared to normal tissue. Tumour stroma also expressed CD151 (Geiserich et al., 2005) . Oncogenesis Refer to 'In vitro studies'.
Neovascularisation/pathologic angiogenesis
Note
Determined from in vivo studies in Cd151-null mice and in vitro studies of Cd151-null mouse lung endothelial cells (Takeda et al., 2007) . Analysis of a rat myocardial ischaemia model also showed that viral delivery of CD151 can promote neovascularisation (Zheng and Liu, 2006) . Disease Cancer, ischaemia Oncogenesis Lack of Cd151 expression resulted in impaired tumour angiogenesis, suggesting that Cd151 may be involved in promoting tumour angiogenesis.
Nephropathy
Note CD151 is expressed normally in the kidney particularly in the glomerular basement membrane (Sincock et al., 1997) .
Disease
Nephropathy in humans (Karamatic Crew et al., 2004) . Cd151-null mice develop progressive renal failure on the FVB/N strain but not the C57BL/6 strain (Sachs et al., 2006; Baleato et al., 2008) . Prognosis Loss of CD151 activity leads to chronic renal failure. Cytogenetics Homozygous frameshift mutation causing a premature stop codon (codon 140) due to the insertion of 1bp in exon 5 of CD151 (G383). Hybrid/Mutated gene Resultant protein lacks the integrin binding domain and causes null expression of the CD151/MER2 antigen (Karamatic Crew et al., 2004) .
Pretibial epidermolysis bullosa
Note
The Nephropathy described above is attributed to the CD151 (CD151 molecule (Raph blood group)) Weidenhofer J, Ashman LK Atlas Genet Cytogenet Oncol Haematol. 2010; 14(6) same mutation in CD151 and occurs in conjunction with pretibial epidermolysis bullosa and deafness (Karamatic Crew et al., 2004) . Wound repair in wild-type mice is associated with an up-regulation of Cd151 in the migrating epidermis at the wound edge (Cowin et al. 2006) . Disease Pretibial epidermolysis bullosa in humans. Defective wound repair in Cd151-null mice (Cowin et al. 2006; Geary et al 2008) . Cytogenetics Homozygous frameshift mutation causing a premature stop codon (codon 140) due to the insertion of 1bp in exon 5 of CD151 (G383). Hybrid/Mutated gene Resultant protein lacks the integrin binding domain and causes null expression of the CD151/MER2 antigen.
Deafness
Note
This loss of function of CD151 is attributed to the same mutation in CD151 as that described above for nephropathy and pretibial epidermolysis bullosa, with all 3 disorders occurring in the same patients (Karamatic Crew et al., 2004) . Prognosis Progressive deafness occurring by early adulthood. Cytogenetics Homozygous frameshift mutation causing a premature stop codon (codon 140) due to the insertion of 1bp in exon 5 of CD151 (G383). Hybrid/Mutated gene Resultant protein lacks the integrin binding domain and causes null expression of the CD151/MER2 antigen.
Hemostasis
Note
As assessed in Cd151-null mice, loss of Cd151 caused increased bleeding time and decreased clotting ability, suggesting endothelial and/or platelet cell functional defects. Cd151-null mice did not show any overt physiological differences unless challenged (Wright et al., 2004) . Further in vitro analysis of Cd151-null platelets showed impaired functions relating to aggregation, spreading and clot retraction (Lau et al., 2004) .
